Foghorn Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $132.08M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $16.10M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $3.30M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $8.20M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $7.60M | $-0.28 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | $6.00M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | After market close | $7.80M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | Before market open | – | – | – |
Press releases
Announcements Foghorn Therapeutics filed with the SEC
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX August 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX May 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX April 2026 Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX March 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Unique biology Precision therapeutics Broad impact FHTX January 2026 NASDAQ LISTED
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
SECURITIES PURCHASE AGREEMENT (the “ Agreement ”) is made as of the 9th day of January, 2026, by and among Foghorn Therapeutics Inc., a Delaware corporation (the “ Company ”), and each of the investors set forth on
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
November 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
November 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99.2
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
October 30, 2025 Virtual Investor Event Pipeline Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
September 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
August 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
May 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
April 29, 2025 • Targeting SMARCA2-Dependent Tumors with FHD-909 (LY4050784) • Advancing Multiple Additional First-in-Class Anticancer Agents AACR April 2025 Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
April 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
March 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
Results of operations · EX-99.1 to Form 8-K
February 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
January 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
December 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Foghorn Therapeutics Provides Third Qu arter 2024 Financial and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
November 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
October 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Foghorn Therapeutics Provides Second Qu arter 2024 Financial and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
August 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K